文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

抗生素的战略重组

Strategic re-engineering of antibiotics.

作者信息

Homer Joshua A, Johnson Robert M, Koelln Rebecca A, Moorhouse Adam D, Moses John E

机构信息

Cancer Center, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA.

出版信息

Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.


DOI:10.1038/s44222-024-00250-w
PMID:40384761
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12083850/
Abstract

Multidrug-resistant bacteria, especially those that defy even last-resort antibiotics, are causing a global health crisis fueled by antibiotic overuse and misuse as well as the lack of new antibiotic development. Multidrug-resistant bacteria compromise our ability to effectively treat infections, impacting medical procedures like surgeries and cancer treatments while increasing illness duration, mortality rates and healthcare costs. In this Review, we discuss reengineering approaches for existing antibiotics to address multidrug-resistant bacterial infections. We outline how antibiotic activity against drug-resistant bacteria can be increased through structural modifications and by engineering polyvalent drugs and combination therapies, designed to overcome drug resistance mechanisms. Finally, we examine regulatory and translational challenges for antibiotic reengineering, highlighting the need for antibiotic stewardship and global guidelines.

摘要

多重耐药菌,尤其是那些对甚至最后手段的抗生素都产生耐药的细菌,正引发一场全球健康危机,这场危机是由抗生素的过度使用和滥用以及新抗生素研发的缺乏所推动的。多重耐药菌损害了我们有效治疗感染的能力,影响了诸如手术和癌症治疗等医疗程序,同时增加了疾病持续时间、死亡率和医疗成本。在本综述中,我们讨论了对现有抗生素进行重新设计以应对多重耐药菌感染的方法。我们概述了如何通过结构修饰以及设计用于克服耐药机制的多价药物和联合疗法来提高抗生素对耐药菌的活性。最后,我们审视了抗生素重新设计在监管和转化方面的挑战,强调了抗生素管理和全球指南的必要性。

相似文献

[1]
Strategic re-engineering of antibiotics.

Nat Rev Bioeng. 2025-3

[2]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[3]
Can We Lower the Burden of Antimicrobial Resistance (AMR) in Heavily Immunocompromised Patients? A Narrative Review and Call to Action.

Infect Dis Ther. 2025-8-7

[4]
Interventions to improve antibiotic prescribing practices for hospital inpatients.

Cochrane Database Syst Rev. 2017-2-9

[5]
Interventions to improve antibiotic prescribing practices for hospital inpatients.

Cochrane Database Syst Rev. 2013-4-30

[6]
Antibiotics for ventilator-associated pneumonia.

Cochrane Database Syst Rev. 2016-10-20

[7]
Antibiotic prophylaxis for preventing bacterial endocarditis following dental procedures.

Cochrane Database Syst Rev. 2022-5-10

[8]
Commercial utilization of bacteriocins: tackling challenges and exploring their potential as alternatives to antibiotics.

Future Microbiol. 2025-6-19

[9]
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.

Cochrane Database Syst Rev. 2022-4-26

[10]
Fabricating mice and dementia: opening up relations in multi-species research

2025-2-25

引用本文的文献

[1]
Antibiotics re-booted-time to kick back against drug resistance.

NPJ Antimicrob Resist. 2025-5-30

本文引用的文献

[1]
Vancomycin-Polyguanidino Dendrimer Conjugates Inhibit Growth of Antibiotic-Resistant Gram-Positive and Gram-Negative Bacteria and Eradicate Biofilm-Associated .

ACS Infect Dis. 2024-2-9

[2]
Exploration of the antibody-drug conjugate clinical landscape.

MAbs. 2023

[3]
Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.

Ann Clin Microbiol Antimicrob. 2023-7-5

[4]
Bifunctional antibiotic hybrids: A review of clinical candidates.

Front Pharmacol. 2023-6-12

[5]
Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.

Antimicrob Agents Chemother. 2023-8

[6]
Antibiotics in the clinical pipeline as of December 2022.

J Antibiot (Tokyo). 2023-8

[7]
Bacterial defences: mechanisms, evolution and antimicrobial resistance.

Nat Rev Microbiol. 2023-8

[8]
Not recommended fixed-dose antibiotic combinations in low- and middle-income countries - the example of Tanzania.

Antimicrob Resist Infect Control. 2023-4-19

[9]
Shapeshifting bullvalene-linked vancomycin dimers as effective antibiotics against multidrug-resistant gram-positive bacteria.

Proc Natl Acad Sci U S A. 2023-4-11

[10]
A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.

Molecules. 2023-2-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索